# Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

> **NCT00051584** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 60 (—)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** SGN-15 (cBR96-Doxorubicin Immunoconjugate)
- **DRUG:** Gemzar (Gemcitabine)

## Key facts

- **NCT ID:** NCT00051584
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 60 (—)
- **Last updated:** 2011-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051584, "Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00051584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*